Fibrosis Scar Formation
Fibrosis Scar Formation - Related Videos
09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
0 Views •
Cited by 11 •
2016
We describe a method to produce an animal model of liver fibrosis in the rat, and assess the degree of fibrosis by histological examination of the liver. The model can be used to study the development of liver disease as well as to test the efficacy of potential anti-fibrotic agents.
01:23
Cystic Fibrosis: Pathogenesis
0 Views •
2024
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body. CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
0 Views •
Cited by 1 •
2025
Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
0 Views •
2025
This protocol demonstrates how the Src homology 2 domain-containing 5'-inositol phosphatase (SHIP)-deficient mouse model of Crohn disease (CD)-like ileal inflammation and fibrosis can be used to test novel therapeutics for CD.
14:56
Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
0 Views •
Cited by 19 •
2012
Attempts to express the cystic fibrosis transmembrane conductance regulator (CFTR) in Saccharomyces cerevisiae have, until now, yielded relatively low amounts of protein. This protocol and the associated reagents distributed via the Cystic Fibrosis Foundation should allow the preparation of milligram amounts of this 'difficult' eukaryotic membrane protein.
FAQs
Transforming growth factor beta acts as a key signal that activates fibroblasts and myofibroblasts after tissue injury. These cells produce extracellular matrix, a structural material rich in collagen, and myofibroblasts also contract that matrix. This coordinated activity can stabilize damaged tissue, but persistent signaling may promote excessive matrix accumulation and progressive tissue stiffening.
Fibroblasts contribute to scar formation by producing collagen-rich extracellular matrix, while myofibroblasts add contractile activity that compacts the developing scar. Their responses help organize tissue around an injury, yet prolonged activation can cause connective tissue to accumulate beyond what repair requires. Studying these cell populations helps explain how healing may shift toward damaging fibrosis.
Persistent inflammation or repeated injury continually supplies signals that maintain fibroblast and myofibroblast activity. Instead of allowing matrix production and contraction to resolve after stabilization, the tissue remains in a repair-oriented state. Continued accumulation of collagen-rich extracellular matrix can increase tissue stiffness, surround functional tissue, and eventually impair organ performance.
In wound healing, scar formation is examined as part of the response that stabilizes damaged tissue. In chronic disease, the same repair-related processes can persist and affect organs such as the liver, lungs, kidneys, and heart. Comparing these settings helps biology researchers distinguish protective repair from progressive scarring that compromises normal organ function.
Biological studies focus on how injury, inflammation, transforming growth factor beta, fibroblasts, myofibroblasts, and extracellular matrix production interact. This research can identify biomarkers associated with scar development and support evaluation of antifibrotic therapies. It also guides strategies designed to promote repair while limiting progressive tissue stiffening and loss of organ function.
A central goal is to preserve the stabilizing benefits of repair without allowing excessive connective tissue to accumulate. Researchers therefore investigate ways to limit progressive fibrosis, maintain tissue flexibility, and protect organ function. Findings may contribute to antifibrotic therapies or repair strategies relevant to chronic disease in the liver, lungs, kidneys, heart, and other organs.